A compound of formula wherein R 1 is selected from a group consisting of: halogen, CN, OH, C 1-6 -alkyl, C 3-7 -cycloalkyl, -(C 1-3 -alkyl)-(C 3-7 -cycloalkyl), -O-(C 1-6 -alkyl), -O-(C 3-7 -cycloalkyl), -O-(C 1-3 -alkyl)-(C 3-7 -cycloalkyl), -O-phenyl,-O-(C 1-3 -alkyl)-phenyl, -COOH, -COO(C 1-4 -alkyl), -CO-NH-(C 1-3 -alkyl)-phenyl, -CO-NH-(C 1-6 -alkyl), -NH-(C 1-6 -alkyl), -NH-(C 3-7 -cycloalkyl), -NH-[(C 1-3 -alkyl)-(C 3-7 -cycloalkyl)] and -NH-(C 1-3 -alkyl)-phenyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents selected from F and CF 3; and wherein the hydrogen atom in each NH group is optionally replaced with C 1-6 -alkyl; or, if two R 1 -groups are attached to adjacent carbon atoms of the phenyl moiety of the tetrahydroisoquinolinyl group, they may be linked with each other and together form a C 3-5 -alkylene bridging group in which 1 or 2 -CH 2 -groups may independently of each other be replaced by -O-, -C(=O)-, -S-, -S(=O)-, -S(=O) 2 -, -NH- or -N(C 1-4 -alkyl)-; n is 0, 1, 2 or 3; R 2 is selected from a group consisting of: H, C 1-6 -alkyl, C 3-7 -cycloalkyl, NH 2,-NH-(C 1-6 -alkyl), -N(C 1-6 -alkyl) 2, -O-(C 1-6 -alkyl), heterocyclyl, 5-membered heteroaryl containing 1 or 2 heteroatoms selected from O, S, N and NH, 6-membered heteroaryl containing one or two nitrogen atoms, and -(C 1-3 -alkyl)-(6-membered heteroaryl containing one or two nitrogen atoms); wherein each alkyl group is optionally substituted with one or more substituents selected from F, CN, CONH 2, CONH(C 1-3 -alkyl), CON(C 1-3 -alkyl) 2, NH 2 and OH, wherein each cycloalkyl group is optionally substituted with one or more substituents selected from F, CN, OH, NH 2, NH OC 1-6 -alkyl, C 1-3 -alkyl and CF 3, wherein each heteroaryl group is optionally substituted with one or more substituents selected from F, Cl, C 1-3 -alkyl, NH 2 and -NH-C -(C 1-3 -alkyl), and wherein the heterocyclyl group is selected from a group consisting of 2-oxo-pyrrolidinyl, 2-oxo-dihydrofuranyl and morpholinyl; R 3 is H or C 1-4 -alkyl-, R 4 is H or C 1-4 -alkyl-, R 5 is H or C 1-3 -alkyl-, R 6 is F, OH or -O-(C 1-4 -alkyl), or, if m is 2, both R 6 groups together with the carbon atom, to which they are attached, may form a carbonyl group; and R 7 is H, C 1-4 -alkyl, -COOH or -COO(C 1-4 -alkyl), and m is 0, 1 or 2; wherein each of the above-mentioned alkyl and -O-alkyl groups may be substituted by one or more F; or a pharmaceutically acceptable salt thereof. R 1 is selected from a group consisting of: halogen, CN, OH, C 1-6 -alkyl, C 3-7 -cycloalkyl, -(C 1-3 -alkyl)-(C 3-7 -cycloalkyl), -O-(C 1-6 -alkyl), -O-(C 3-7 -cycloalkyl), -O-(C 1-3 -alkyl)-(C 3-7 -cycloalkyl), -O-phenyl,-O-(C 1-3 -alkyl)-phenyl, -COOH, -COO(C 1-4 -alkyl), -CO-NH-(C 1-3 -alkyl)-phenyl, -CO-NH-(C 1-6 -alkyl), -NH-(C 1-6 -alkyl), -NH-(C 3-7 -cycloalkyl), -NH-[(C 1-3 -alkyl)-(C 3-7 -cycloalkyl)] and -NH-(C 1-3 -alkyl)-phenyl, wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents selected from F and CF 3; and wherein the hydrogen atom in each NH group is optionally replaced with C 1-6 -alkyl; wherein each alkyl and cycloalkyl is optionally substituted with one or more substituents selected from F and CF 3; and wherein the hydrogen atom in each NH group is optionally replaced with C 1-6 -alkyl; n is 0, 1, 2 or 3; R 2 is selected from a group consisting of: H, C 1-6 -alkyl, C 3-7 -cycloalkyl, NH 2,-NH-(C 1-6 -alkyl), -N(C 1-6 -alkyl) 2, -O-(C 1-6 -alkyl), heterocyclyl, 5-membered heteroaryl containing 1 or 2 heteroatoms selected from O, S, N and NH, 6-membered heteroaryl containing one or two nitrogen atoms, and -(C 1-3 -alkyl)-(6-membered heteroaryl containing one or two nitrogen atoms); wherein each alkyl group is optionally substituted with one or more substituents selected from F, CN, CONH 2, CONH(C 1-3 -alkyl), CON(C 1-3 -alkyl) 2, NH 2 and OH, wherein each cycloalkyl group is optionally substituted with one or more substituents selected from F, CN, OH, NH 2, NH OC 1-6 -alkyl, C 1-3 -alkyl and CF 3, wherein each heteroaryl group is optionally substituted with one or more substituents selected from F, Cl, C 1-3 -alkyl, NH 2 and -NH-C -(C 1-3 -alkyl), and wherein the heterocyclyl group is selected from a group consisting of 2-oxo-pyrrolidinyl, 2-oxo-dihydrofuranyl and morpholinyl; wherein each alkyl group is optionally substituted with one or more substituents selected from F, CN, CONH 2, CONH(C 1-3 -alkyl), CON(C 1-3 -alkyl) 2, NH 2 and OH, wherein each cycloalkyl group is optionally substituted with one or more substituents selected from F, CN, OH, NH 2, NH OC 1-6 -alkyl, C 1-3 -alkyl and CF 3, wherein each heteroaryl group is optionally substituted with one or more substituents selected from F, Cl, C 1-3 -alkyl, NH 2 and -NH-C -(C 1-3 -alkyl), and wherein the heterocyclyl group is selected from a group consisting of 2-oxo-pyrrolidinyl, 2-oxo-dihydrofuranyl and morpholinyl; R 3 is H or C 1-4 -alkyl-, R 4 is H or C 1-4 -alkyl-, R 5 is H or C 1-3 -alkyl-, R 6 is F, OH or -O-(C 1-4 -alkyl), or, if m is 2, both R 6 groups together with the carbon atom, to which they are attached, may form a carbonyl group; and R 7 is H, C 1-4 -alkyl, -COOH or -COO(C 1-4 -alkyl), and m is 0, 1 or 2;